Actively Recruiting
PSMA PET for Surveillance After Focal Therapy
Led by University of Chicago · Updated on 2026-02-17
62
Participants Needed
1
Research Sites
140 weeks
Total Duration
On this page
Sponsors
U
University of Chicago
Lead Sponsor
B
Blue Earth Diagnositcs
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is about adding PSMA PET (Prostate Specific Membrane Antigen- Positron Emission Tomography) to routine magnetic resonance imaging (MRI) scans to help detect prostate cancer recurrence in men who have undergone focal therapy for prostate cancer. PSMA PET and multiparametric (mpMRI are both imaging tests that help detect prostate cancer in the body. A PSMA PET scan, or prostate-specific membrane antigen positron emission tomography scan, is an imaging test that scans and takes pictures of the prostate. PSMA scans use a specialized radioactive imaging dye that sticks to the proteins that are typically found in prostate cancer cells. This imaging dye helps locate areas of prostate cancer anywhere in the body, both inside and outside prostate. An mpMRI, or a multiparametric (mp) MRI scan, is also an imaging test that scans and takes detailed pictures of the prostate. Unlike regular MRIs, an mpMRI produces a more detailed image of the prostate. Similar to PET scans, mpMRI scans also use an imaging dye that helps the pictures of the prostate appear clearer on scans. This study will be funded by Blue Earth Diagnostics, a molecular imaging company based in England.
CONDITIONS
Official Title
PSMA PET for Surveillance After Focal Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male, assigned male at birth, age 18 years or older
- Ability to understand and provide written informed consent
- Histologically confirmed prostate cancer by prostate biopsy within 1 year prior to consent
- Chosen to receive focal therapy (partial gland ablation) within 6 months following consent
- Confirmed non-metastatic prostate cancer by standard imaging within 6 months of enrollment
- Eastern Cooperative Oncology Group (ECOG) performance status 64 2 or Karnofsky score 50%
- Fit for general anesthesia and focal therapy surgery with adequate prostate visualization and tolerance of lithotomy position
You will not qualify if you...
- Received prostate cancer treatments (biologic, chemotherapy, hormone therapy, radiotherapy, or surgery) within the last 12 months
- Locally advanced, nodal, or metastatic prostate cancer
- Unfit for pelvic mpMRI due to claustrophobia, pacemaker, metallic implants causing artifacts, or allergy to gadolinium contrast
- Uncontrolled or major debilitating illness
- Judged unsuitable to participate or unlikely to comply with study procedures by investigator or principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
A
Abhinav Sidana, MD
CONTACT
A
Abhinav Sidana, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here